AFT Licenses Maxigesic IV in China and USA update

AFT Pharmaceuticals Limited,
Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com








30 September 2024
AFT Licenses Maxigesic
®
IV in China and USA update.
China: AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today announces the
exclusive licensing of Maxigesic IV, the intravenous form of its proprietary pain
relief medicine, for China, the largest pharma market in Asia and the

second
largest pharma market in the world
1
.
AFT Pharmaceuticals Managing Director Dr Hartley Atkinson said: “We are
delighted to announce our partnership with China’s Xizang Weixinkang
Pharmaceutical Co Ltd (WXK), an established hospital injectables focused
company in China and listed on the Shanghai Stock Exchange main board
(Code 6063676.SH). It is the ideal partner for this market, due to its existing
hospital business in China.”
AFT anticipates receiving various licence payments from the agreement being
a US$300,000 signing payment, development milestone payments, sales
milestone payments and royalty payments based on net sales in China
2,3
.

USA: AFT’s US licensee, Hikma Pharmaceuticals has announced
4
receipt of a
Permanent J-code, effective 1 October 2024, for Combogesic
®
IV (alternative
brand name for Maxigesic) from Centers for Medicare & Medicaid Services
(CMS). Dr Bill Larkins, Hilkma President of Injectables said: “We are pleased with
the Combogesic IV J-code assignment, as it will aid healthcare providers in
billing and reimbursement, better supporting patient access to treatment for
adult pain management.”

AFT has now out-licensed or made its own distribution arrangements for
Maxigesic IV in nine of the top Pharma markets in the world: USA, Germany,
France, Italy, UK (AFT Pharma UK Ltd), Canada (AFT Pharma Canada Ltd),
Spain, Brazil and now China.


Footnotes
1.https://www.statista.com/statistics/245473/market-share-of-the-leading-10-global-
pharmaceutical-markets/
2. AFT development partner Hyloris Pharmaceuticals receives a minority share of proceeds
3. Licensing negotiations enabled by Ms Hong Xie, Pharma China Consulting

AFT Pharmaceuticals Limited,
Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

4. https://www.hikma.com/news/hikma-pharmaceuticals-receives-permanent-j-code-for-
combogesic-iv-acetaminophen-and-ibuprofen-injection-from-centers-for-medicare-
medicaid-services-cms/


For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial
Officer.

For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

About AFT Pharmaceuticals
AFT is a growing New Zealand based multinational pharmaceutical company that
develops, markets, and distributes a broad portfolio of pharmaceutical products
across a wide range of therapeutic categories which are distributed across all major
pharmaceutical distribution channels: over the counter (OTC), prescription and
hospital. Our product portfolio comprises both proprietary and in-licensed products,
and includes patented, branded, and generic drugs
1
. Our business model is to
develop and in-license products for in our markets of Australia, New Zealand,
Singapore, Malaysia, Hong Kong, USA, Canada, EU ex Ireland and UK, and to out-
license our products to local licensees and distributors to over 125 countries around
the world. For more information about the company, visit our website
www.aftpharm.com.


About WXK
Xijang Weixinkang Pharmaceutical Co Ltd was established in 2002, officially founded
in 2006, Xizang Weixinkang Pharmaceutical Co., Ltd is listed on the mainboard of the
Shanghai Stock Exchange (stock code 603676.SH) in 2017, with 13 subsidiaries and
nearly 800 employees, distributed in Beijing, Xizang, Inner Mongolia, Hainan, Jiangsu,
Hong Kong, Singapore and other places